247 related articles for article (PubMed ID: 27001529)
1. Core size determination and structural characterization of intravenous iron complexes by cryogenic transmission electron microscopy.
Wu Y; Petrochenko P; Chen L; Wong SY; Absar M; Choi S; Zheng J
Int J Pharm; 2016 May; 505(1-2):167-74. PubMed ID: 27001529
[TBL] [Abstract][Full Text] [Related]
2. Ferrous iron content of intravenous iron formulations.
Gupta A; Pratt RD; Crumbliss AL
Biometals; 2016 Jun; 29(3):411-5. PubMed ID: 26956439
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical Characterization of Iron Carbohydrate Colloid Drug Products.
Zou P; Tyner K; Raw A; Lee S
AAPS J; 2017 Sep; 19(5):1359-1376. PubMed ID: 28762128
[TBL] [Abstract][Full Text] [Related]
4. A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.
Coppol E; Shelly J; Cheng S; Kaakeh Y; Shepler B
Ann Pharmacother; 2011 Feb; 45(2):241-7. PubMed ID: 21304025
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications.
Jahn MR; Andreasen HB; Fütterer S; Nawroth T; Schünemann V; Kolb U; Hofmeister W; Muñoz M; Bock K; Meldal M; Langguth P
Eur J Pharm Biopharm; 2011 Aug; 78(3):480-91. PubMed ID: 21439379
[TBL] [Abstract][Full Text] [Related]
6. Iron sucrose: assessing the similarity between the originator drug and its intended copies.
Di Francesco T; Philipp E; Borchard G
Ann N Y Acad Sci; 2017 Nov; 1407(1):63-74. PubMed ID: 29168243
[TBL] [Abstract][Full Text] [Related]
7. A robust and easily reproducible protocol for the determination of size and size distribution of iron sucrose using dynamic light scattering.
Di Francesco T; Borchard G
J Pharm Biomed Anal; 2018 Apr; 152():89-93. PubMed ID: 29414023
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of sub-micron poly(D,L-lactide-co-glycolide) particles loaded with magnetite/maghemite nanoparticles.
Ngaboni Okassa L; Marchais H; Douziech-Eyrolles L; Cohen-Jonathan S; Soucé M; Dubois P; Chourpa I
Int J Pharm; 2005 Sep; 302(1-2):187-96. PubMed ID: 16099119
[TBL] [Abstract][Full Text] [Related]
9. Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD).
Fütterer S; Andrusenko I; Kolb U; Hofmeister W; Langguth P
J Pharm Biomed Anal; 2013 Dec; 86():151-60. PubMed ID: 23998966
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical characterization and thermodynamic stability assessment of a colloidal iron drug product: iron sucrose.
Shah RB; Yang Y; Khan MA; Raw A; Yu LX; Faustino PJ
Int J Pharm; 2014 Apr; 464(1-2):46-52. PubMed ID: 24440404
[TBL] [Abstract][Full Text] [Related]
11. Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products.
Wang C; Graham DJ; Kane RC; Xie D; Wernecke M; Levenson M; MaCurdy TE; Houstoun M; Ryan Q; Wong S; Mott K; Sheu TC; Limb S; Worrall C; Kelman JA; Reichman ME
JAMA; 2015 Nov; 314(19):2062-8. PubMed ID: 26575062
[TBL] [Abstract][Full Text] [Related]
12. Practical aspects in size and morphology characterization of drug-loaded nano-liposomes.
Peretz Damari S; Shamrakov D; Varenik M; Koren E; Nativ-Roth E; Barenholz Y; Regev O
Int J Pharm; 2018 Aug; 547(1-2):648-655. PubMed ID: 29913218
[TBL] [Abstract][Full Text] [Related]
13. Labile iron in parenteral iron formulations: a quantitative and comparative study.
Van Wyck D; Anderson J; Johnson K
Nephrol Dial Transplant; 2004 Mar; 19(3):561-5. PubMed ID: 14767009
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate.
Brandis JEP; Kihn KC; Taraban MB; Schnorr J; Confer AM; Batelu S; Sun D; Rodriguez JD; Jiang W; Goldberg DP; Langguth P; Stemmler TL; Yu YB; Kane MA; Polli JE; Michel SLJ
Mol Pharm; 2021 Apr; 18(4):1544-1557. PubMed ID: 33621099
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
[TBL] [Abstract][Full Text] [Related]
16. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose.
Neiser S; Rentsch D; Dippon U; Kappler A; Weidler PG; Göttlicher J; Steininger R; Wilhelm M; Braitsch M; Funk F; Philipp E; Burckhardt S
Biometals; 2015 Aug; 28(4):615-35. PubMed ID: 25801756
[TBL] [Abstract][Full Text] [Related]
17. Nitrosative Stress and Apoptosis by Intravenous Ferumoxytol, Iron Isomaltoside 1000, Iron Dextran, Iron Sucrose, and Ferric Carboxymaltose in a Nonclinical Model.
Toblli JE; Cao G; Giani JF; Dominici FP; Angerosa M
Drug Res (Stuttg); 2015 Jul; 65(7):354-60. PubMed ID: 25050519
[TBL] [Abstract][Full Text] [Related]
18. Relaxometric and magnetic characterization of ultrasmall iron oxide nanoparticles with high magnetization. Evaluation as potential T1 magnetic resonance imaging contrast agents for molecular imaging.
Taboada E; Rodríguez E; Roig A; Oró J; Roch A; Muller RN
Langmuir; 2007 Apr; 23(8):4583-8. PubMed ID: 17355158
[TBL] [Abstract][Full Text] [Related]
19. Physicochemical properties of ferumoxytol, a new intravenous iron preparation.
Balakrishnan VS; Rao M; Kausz AT; Brenner L; Pereira BJ; Frigo TB; Lewis JM
Eur J Clin Invest; 2009 Jun; 39(6):489-96. PubMed ID: 19397688
[TBL] [Abstract][Full Text] [Related]
20. Physicochemical and structural characterization of iron-sucrose formulations: a comparative study.
Barot BS; Parejiya PB; Mehta DM; Shelat PK; Shah GB
Pharm Dev Technol; 2014 Aug; 19(5):513-20. PubMed ID: 23701359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
